Novo Nordisk and its Chinese partner, The United Laboratories, have reported promising mid-phase results for their triple-G candidate, UBT251, demonstrating significant efficacy in Type 2 diabetes management. In a phase 2 trial involving 211 patients, UBT251 achieved a reduction in HbA1c levels of up to 2.16% after 24 weeks, outperforming semaglutide, Novo’s existing GLP-1 therapy, which showed a 1.77% reduction. Additionally, participants on UBT251 experienced mean body weight reductions of up to 9.8%, compared to 4.8% for semaglutide.

This development is particularly relevant as the competitive landscape intensifies with Eli Lilly’s retatrutide, which has shown even greater efficacy in weight loss and diabetes management. With Lilly poised to file for FDA approval of retatrutide, the timing of UBT251’s entry into the market raises questions about its commercial viability.

For longevity professionals, the key takeaway is the importance of ongoing clinical trial data in shaping therapeutic landscapes, particularly as competing candidates emerge in the obesity and diabetes treatment space.

Source: fiercebiotech.com